Protagonist Therapeutics, Inc Foreign Income Tax Expense (Benefit), Continuing Operations
Protagonist Therapeutics, Inc (PTGX) reported Foreign Income Tax Expense (Benefit), Continuing Operations of -$1.10 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2020-11-04.
Discontinued › Expense Statement › Income Tax
us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2020-11-04
- Protagonist Therapeutics, Inc foreign income tax expense (benefit), continuing operations for the quarter ending 2019-09-30 was $0.00.
- Protagonist Therapeutics, Inc foreign income tax expense (benefit), continuing operations for the quarter ending 2019-06-30 was -$1.10M.
| Period end | Foreign Income Tax Expense (Benefit), Continuing Operations 3 month | Foreign Income Tax Expense (Benefit), Continuing Operations 6 month | Foreign Income Tax Expense (Benefit), Continuing Operations 9 month |
|---|---|---|---|
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$1.10M derived: sum of 2 quarters · filed 2020-11-04 | -$1.10M 10-Q · filed 2020-11-04 |
| 2019-06-30 | -$1.10M 10-Q · filed 2020-08-06 | -$1.10M 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |